JECX • PT Nitrasanata Dharma Tbk IPO Unwrap: BUY or BYE?

Author: aluna Analytics | Date: 22 June 2026 | Sector: Healthcare (Hospitals & Clinics) | Recommendation: Underweight / High Risk

However, the internal composition of this offering volume warrants intense analytical scrutiny, as it is bifurcated into two distinct tranches with fundamentally different implications for corporate capitalization. The primary capital raising component consists of 325,322,300 newly issued shares originating directly from the company’s unissued portfolio, representing 10.00% of the post-offering capital. Concurrently, the transaction features a substantial secondary divestment component, comprising 162,661,200 existing shares, which equates to 5.00% of the post-offering capital. This secondary tranche is being offered exclusively by a single selling shareholder, DR. Dr. Waldensius Girsang, SpM(K), a prominent medical professional and early stakeholder within the organization.

The implications of this structural bifurcation are profound. Assuming the transaction prices at the upper boundary of the established range at Rp1,400 per share, the offering will generate maximum total gross proceeds of approximately Rp683.17 billion. However, the actual liquidity flowing into the corporate treasury to fund operations and structural reorganization is strictly limited to the primary tranche proceeds, which cap at approximately Rp455.45 billion. The remaining Rp227.72 billion generated by the secondary tranche will bypass the corporate balance sheet entirely, accruing directly to the personal wealth of the selling shareholder. From an institutional investment perspective, this structure indicates that fully one-third of the market’s absorbed liquidity in this transaction will not contribute to the enterprise’s future growth trajectory, debt resolution, or operational scaling, thereby diluting the fundamental utility of the capital raise. The transaction is notably devoid of any attached derivative instruments such as warrants, which provides a degree of comfort by eliminating the risk of future, uncompensated equity dilution.

Operating in parallel with the public offering is a highly structured Employee Stock Allocation (ESA) program. The company has formally earmarked 2.29% of the total offered shares, which translates to an absolute volume of 11,165,000 shares, specifically for distribution to eligible personnel. The mechanical execution of this program relies on a staggered, performance-contingent vesting schedule spanning a four-year horizon commencing from the date of the IDX listing. Annually, up to 25.00% of the allocated shares become eligible for vesting, but the actual realization of these shares is rigidly tethered to individualized Key Performance Indicator assessments. Participants achieving a “Good” rating are entitled to 60.00% of their annual vesting tranche, those rated “Outstanding” secure 80.00%, and only those demonstrating “Exceptional” performance capture the full 100.00% allocation. Conversely, ratings of “Poor” or “Fair” result in the total forfeiture of the annual tranche. The company assumes the financial burden of all transaction costs and final taxes associated with the ESA distribution. While the absolute dilutive impact of 11.16 million shares is mathematically negligible within a multi-billion share capitalization structure, the strategic intent of the ESA is critical. In the specialized realm of tertiary ophthalmology, where the recruitment and retention of elite surgical talent and highly trained nursing staff form the absolute bedrock of operational continuity and brand equity, the ESA program functions as an indispensable mechanism to align human capital incentives with long-term shareholder value creation and to structurally mitigate the severe risk of key-personnel attrition to rival healthcare networks.

Disclaimer: This research report is produced by aluna Analytics for informational and educational purposes only. It does not constitute a recommendation to buy or sell any securities. Market data is analyzed as of June 22, 2026. Investors should conduct their own due diligence and consult with a certified financial advisor before making investment decisions.

Capital Allocation and Utilization of Proceeds

The deployment architecture for the primary proceeds further crystallizes the underlying motivations driving this public market debut. An intense examination of the intended use of proceeds reveals a capital allocation strategy dominated by aggressive balance sheet deleveraging rather than organic or inorganic capacity expansion.

From the estimated Rp455.45 billion in primary funds, the management has mandated that Rp40.0 billion be deployed for the accelerated principal repayment of existing debt facilities with PT Bank Central Asia Tbk. A significantly larger tranche of Rp100.0 billion is dedicated to the early retirement of principal obligations owed to PT Bank HSBC Indonesia. The corporate deleveraging extends deeply into the subsidiary architecture, with approximately Rp185.0 billion allocated for downward distribution. Within this subsidiary allocation, PT Nitra Sanata Bali will receive a direct capital injection of approximately Rp50.0 billion, primarily to satisfy land lease obligations and cover localized payroll expenses. More critically, PT Orbita will receive a shareholder loan of Rp100.0 billion, and PT JEC Candi Sejahtera will receive a similar loan of Rp35.0 billion. The explicit, singular purpose of both intercompany loans is to enable these subsidiaries to immediately pay down their respective outstanding principal balances with PT Bank Central Asia Tbk.

Any residual capital remaining after these debt extinguishments and specific subsidiary injections will be absorbed into the parent company’s general working capital pool to subsidize daily operational expenditures, specifically payroll and employee benefits, stretching into the end of the 2027 fiscal year. This allocation matrix provides an unmistakable signal to the institutional investment community: this initial public offering is fundamentally engineered as a comprehensive rescue operation designed to repair a structurally stressed, over-leveraged consolidated balance sheet. The overwhelming prioritization of debt repayment over capital expenditure for new hospital construction, technological acquisition, or geographic expansion severely constrains the narrative that this IPO is a growth-oriented capital raise, framing it instead as a necessary financial restructuring event executed via the public equities market.

Supply-Demand Mechanics and Capitalization Vulnerabilities

Transitioning the analytical focus toward the ownership dynamics and the resultant supply-demand equilibrium provides the critical framework for evaluating immediate aftermarket stability. The capitalization table of PT Nitrasanata Dharma Tbk prior to the public offering exhibits an unusual degree of fragmentation, characterized by a complex interplay between institutional conglomerate interests and a vast diaspora of individual medical practitioners. The dominant institutional anchor is PT Sarana Meditama Metropolitan Tbk ($SAME), which operates within the Emtek conglomerate’s healthcare ecosystem and holds a commanding 28.00% equity stake. This strategic position was established through an acquisition in 2022, effectively embedding the JEC network within a broader, national healthcare infrastructure. The formally designated controlling shareholder of the enterprise is PT Magna Selaras Lestari, maintaining a 10.149% stake, while the ultimate beneficial owner exerting supreme strategic influence is identified as Dr. Darwan Madja Purba, SpM, holding 13.105% directly.

The remainder of the pre-IPO equity is distributed among several dozen individual shareholders, almost exclusively comprising specialized ophthalmologists and medical administrators. Notable individual holdings include Rayyan Farrel Wardhana Istiantoro and Nabbil Wardhana Istiantoro, each holding 9.886%, the selling shareholder DR. Dr. Waldensius Girsang with 6.216%, Prof. DR. Dr. Widya Artini Wijogo with 3.695%, and Drg. Rifi Aranti with 2.999%, cascading down to minority fractions held by numerous other clinical practitioners. Following the issuance of the primary shares, the total outstanding share count will inflate to 3,253,222,300 shares. The formal free float introduced to the public market will stand at 15.00%, supplemented marginally by the 2.29% ESA distribution over time.

The presence of the secondary divestment fundamentally alters the supply-demand calculus of the transaction. By liquidating 162,661,200 shares, DR. Dr. Waldensius Girsang is engineering a massive personal liquidity event concurrently with the company’s capitalization effort. In a capital market environment where initial public offerings rely heavily on the perception of total insider alignment and unwavering confidence in the post-listing valuation trajectory, the deliberate extraction of nearly Rp228.0 billion by a prominent insider introduces profound skepticism. This secondary exit guarantees that a massive block of effective supply will enter the market immediately upon listing, requiring substantial and sustained institutional demand to absorb the paper and prevent rapid price deterioration.

Furthermore, the fragmented nature of the pre-IPO shareholder base creates a highly unstable behavioral dynamic. While the institutional stakeholder, PT Sarana Meditama Metropolitan Tbk ($SAME), is strategically incentivized to maintain a long-term hold to extract operational synergies and consolidate market share within the Emtek ecosystem, the dozens of individual medical professionals hold no such mandate. For these individual practitioners, the IPO represents the first opportunity in the organization’s four-decade history to convert illiquid private shares into highly liquid public securities. This structural reality shifts the balance of probability toward aggressive monetization by minority insiders, threatening to flood the secondary market with uncoordinated supply should the stock exhibit any early price appreciation.

Regulatory Architecture and the Lock-Up Overhang

The ultimate determinant of post-listing supply pressure lies in the mechanical enforcement of equity lock-up provisions. A forensic regulatory analysis of the prospectus, evaluated strictly against the parameters of the Financial Services Authority Regulation POJK No. 25/POJK.04/2017 concerning the Restriction on Shares Issued Prior to a Public Offering, reveals a catastrophic vulnerability in the transaction’s defense against insider selling. The OJK regulation explicitly dictates that any party acquiring equity at a valuation lower than the final IPO offering price within a specific six-month window immediately preceding the initial registration filing is legally prohibited from transferring those shares for a mandatory period of eight months following the effective date.

However, the corporate disclosures emphatically confirm that no party, institutional or individual, has acquired newly issued shares from the company at a price inferior to the IPO range within this critical six-month antecedent window. Consequently, the mandatory regulatory lock-up mechanism envisioned by POJK No. 25/2017 is entirely void and inapplicable to every single existing shareholder on the capitalization table. To partially address this glaring regulatory vacuum, the officially designated controlling shareholder, PT Magna Selaras Lestari, has executed a voluntary negative covenant, formally pledging to maintain its controlling status and abstain from liquidating its equity for a period of twelve months post-listing.

The systemic implication of this framework is severe and represents the single greatest structural risk to prospective investors. The voluntary restriction applies exclusively to the 10.149% stake held by the controller. This mathematically dictates that approximately 74.85% of the total outstanding post-IPO equity—encompassing the 28.00% strategic block held by PT Sarana Meditama Metropolitan Tbk, the 13.105% held by the ultimate beneficial owner, and the vast mosaic of holdings belonging to the individual medical practitioners—is entirely free from any legal, regulatory, or voluntary encumbrance.

If the secondary market experiences an initial surge in price discovery, the total absence of lock-up constraints on three-quarters of the company’s equity provides absolute legal clearance for these stakeholders to execute immediate, massive liquidations. This dynamic completely circumvents the traditional post-IPO seasoning period, introducing the immediate threat of a catastrophic cliff effect on the very first day of trading. The architecture of the lock-up provisions fails fundamentally to secure ownership stability, transforming what should be a constrained float into a heavily over-supplied marketplace susceptible to extreme downward volatility driven by insider exits.

Quantitative Underwriting Signals and Syndicate Evaluation

Aluna Analytics Insight: LG’s statistical profile is extraordinarily dominant. They boast a staggering Weighted Winrate of aluna Plus███████ aluna Plus Exclusive This content is exclusive for aluna Plus (Registered Members). Join for FREE to unlock access. Register for Free and a Conventional Winrate of 95.24%. When operating as a Solo underwriter (as they are in the JECX offering), their historical performance projects a Day 1 return of 27.91% and a massive Day 7 projected return of aluna Plus███████ aluna Plus Exclusive This content is exclusive for aluna Plus (Registered Members). Join for FREE to unlock access. Register for Free . Crucially, LG maintains a perfect Liquidity Score of aluna Prime███████ aluna Prime Exclusive Advanced analytical data is exclusively available for aluna Prime members. Starting from IDR 10K. Unlock Prime Access and a Guardian Score of aluna Prime█████ aluna Prime Exclusive Advanced analytical data is exclusively available for aluna Prime members. Starting from IDR 10K. Unlock Prime Access , signaling an absolute capacity and historical willingness to aggressively defend offering prices and absorb dumping pressure in the immediate aftermarket.

The injection of LG’s quantitative profile into the transaction analysis drastically alters the risk calculus. In the context of an IPO characterized by a massive Rp683.0 billion float, a heavy secondary divestment tranche, and an alarming absence of lock-up restrictions on 75% of pre-IPO shares, LG acts as the ultimate mitigant. The structural supply overhang is severe, but LG’s “King Maker” status and aluna Plus███████ aluna Plus Exclusive This content is exclusive for aluna Plus (Registered Members). Join for FREE to unlock access. Register for Free Liquidity Score strongly suggest they have the dedicated capital pools and syndicate discipline required to absorb the incoming paper from un-locked insiders and force an upward price discovery trajectory, at least in the initial days of trading (averaging aluna Plus█████ aluna Plus Exclusive This content is exclusive for aluna Plus (Registered Members). Join for FREE to unlock access. Register for Free days until reversal).

Structural Preliminary Judgment

Synthesizing the mechanical and structural components analyzed thus far yields a highly volatile, yet fiercely contested preliminary judgment. The core transaction architecture is intrinsically hostile to secondary market stability. The offering is exceptionally supply-heavy, burdened immediately by a substantial secondary exit that siphons vital liquidity away from corporate utility. The capital allocation strategy, overwhelmingly dedicated to extinguishing breached bank debt, paints a picture of a distressed balance sheet seeking emergency public relief.

This precarious setup is exponentially compounded by the catastrophic lack of lock-up provisions covering nearly 75% of the pre-IPO equity, creating a looming, unconstrained supply overhang composed of dozens of individual insiders. However, the presence of PT Trimegah Sekuritas Indonesia Tbk (LG) as the sole underwriter introduces a titan into the arena. LG’s 96.51% winrate and flawless liquidity metrics indicate that the underwriter is heavily incentivized and fully capable of defending the Rp1,400 valuation, converting a structurally perilous IPO into a high-probability short-term trading vehicle, albeit one fraught with long-term insider exit risks once the underwriter’s stabilization window closes.

Enterprise Fundamentals and Strategic Positioning

Transitioning the analytical focus toward the underlying corporate entity, PT Nitrasanata Dharma Tbk operates the JEC Eye Hospitals and Clinics network, universally recognized as the premier, highly specialized ophthalmology franchise within the Indonesian archipelago. Originating from a single facility known as Klinik Mata Jakarta established in 1984, the enterprise has systematically scaled over four decades into a formidable, vertically integrated healthcare network comprising four fully equipped specialty hospitals and nine advanced clinical centers strategically distributed across Java, Bali, and Sulawesi. The operational zenith of this network is the JEC Kedoya facility, which holds the globally prestigious Joint Commission International (JCI) accreditation, providing an irrefutable validation of its rigorous clinical governance, advanced infection control protocols, and unwavering commitment to patient safety.

The business model is meticulously architected around a hub-and-spoke continuum of care, designed to capture value across the entire spectrum of ophthalmic intervention. The revenue streams are deeply diversified within the specialty, driven heavily by complex, high-margin surgical procedures including advanced phacoemulsification for cataracts, intricate vitreoretinal surgeries, glaucoma filtration interventions, and state-of-the-art refractive corrections such as LASIK and SMILE procedures. These high-acuity surgical revenues are systematically supported by high-volume outpatient clinical consultations, comprehensive diagnostic imaging, and an integrated, highly profitable optical dispensary and pharmaceutical division. The company leverages sophisticated digital patient journey mapping and integrated data analytics to optimize clinical throughput, minimize patient friction, and maximize lifetime value retention.

Despite this commanding market position, the corporate profile is characterized by profound, existential concentration risks revolving around human capital. The operational viability and brand equity of the entire enterprise are inextricably linked to the recruitment, continuous training, and long-term retention of a highly specialized medical workforce. The prospectus explicitly identifies the dependence on key doctors, specialized nursing staff, and medical professionals as the apex risk factor threatening the organization. Operating in a nation with a population approaching 280 million but possessing only approximately 2,295 registered ophthalmologists, the competition for elite surgical talent is intensely fierce. The company attempts to structurally mitigate this constraint through several mechanisms: integrating key medical personnel directly into the capitalization table as shareholders, implementing the aforementioned ESA program to create performance-based golden handcuffs, and establishing its flagship hospitals as primary educational and fellowship facilities to cultivate a proprietary pipeline of future specialists.

Strategically, the integration of PT Sarana Meditama Metropolitan Tbk as a 28.00% anchor stakeholder fundamentally alters the company’s positioning. As a core component of the Emtek conglomerate’s EMC Healthcare ecosystem, the JEC network gains access to vast, cross-institutional patient referral pathways, shared capital-intensive technological infrastructure, and massively enhanced procurement leverage for pharmaceuticals and medical consumables. This alliance positions JEC not merely as an isolated specialty provider, but as the dedicated ophthalmic pillar within one of Indonesia’s most aggressive corporate healthcare consolidators.

Macroeconomic Dependencies and Sectoral Headwinds

Fundamental Earnings Trajectory and Asset Quality

A rigorous, granular examination of the consolidated financial statements reveals a complex profile characterized by steady top-line expansion, severe recent margin compression, and a deeply stressed capital structure requiring immediate remediation.

The consolidated revenue trajectory exhibits resilient, albeit visibly decelerating, growth. Gross revenues expanded by 7.59% from Rp825.08 billion in 2023 to Rp887.71 billion in 2024, followed by a more constrained 4.40% expansion to Rp926.76 billion in the fiscal year 2025. This sustained top-line growth was fundamentally driven by consistent, year-over-year increases in aggregate patient volumes, which culminated in 564,526 clinical visits and 51,530 surgical procedures by the end of 2025.

Despite this revenue resilience, the quality of earnings has experienced shocking volatility, indicating significant operational friction. The consolidated net profit contracted precipitously, plummeting by approximately 50.9% from a robust Rp127.28 billion in 2023 to a mere Rp62.47 billion in 2024. Management commentary attributes this severe profitability erosion to the aggressive scaling of operational expenditures, explicitly citing a massive surge in clinical payroll, specialized professional fees, and heightened consumable supply costs associated with the aggressive commissioning and staffing of new clinical facilities. While net profit demonstrated a partial, stabilization-driven recovery to Rp72.60 billion in 2025, representing a 16.2% year-over-year improvement, the resulting net profit margin of 7.83% remains vastly inferior to the 15.42% margin achieved during the historical peak of 2023. This prolonged margin compression suggests that the company is struggling to achieve operational leverage as it scales its geographic footprint.

Cash flow generation, however, remains a core fundamental strength, temporarily masking the depth of the margin issues. Operating cash flows remained solidly positive at Rp173.35 billion in 2025, providing vital liquidity to cover routine maintenance capital expenditures. Nevertheless, despite this cash-generating capacity, the balance sheet has become critically impaired by escalating debt burdens incurred to finance the aggressive recent infrastructure expansions. Total consolidated liabilities expanded sequentially across the three-year period, reaching Rp640.33 billion by the close of 2025.

Crucially, the prospectus disclosures regarding financial durability expose severe covenant breaches affecting the company’s primary credit facilities. As of December 31, 2025, the parent entity, PT Nitrasanata Dharma Tbk, formally breached the minimum debt service coverage ratio and the maximum debt-to-equity ratio stipulated by its primary lender, PT Bank Central Asia Tbk. Concurrently, key operational subsidiaries, including PT JEC Candi Sejahtera and PT Orbita, similarly violated strict interest coverage and leverage covenants. Although the creditors issued formal waiver letters in March 2026 to prevent the immediate acceleration of default proceedings, the documented presence of these severe violations completely dismantles any cosmetic presentation of financial strength. It illuminates the true, unvarnished catalyst for this IPO: the absolute, urgent necessity to inject massive public equity to cure a structurally distressed balance sheet, pacify institutional lenders, and avert a comprehensive liquidity crisis.

Comparative Valuation and Pricing Realities

Evaluating the equity pricing demands contextualizing the aggressive offering multiples against the stark reality of the company’s recent margin compression, covenant breaches, and the prevailing valuations of the broader domestic healthcare sector.

At the prescribed bookbuilding price range of Rp1,200 to Rp1,400 per share, and assuming the successful issuance of the maximum 325,322,300 primary shares, the enlarged outstanding share count will reach exactly 3,253,222,300 shares. This architecture translates to an implied post-money market capitalization ranging from Rp3.90 trillion at the lower boundary to an imposing Rp4.55 trillion at the absolute maximum price. Applying the finalized 2025 consolidated net profit of Rp72.60 billion to this capitalization structure, the offering demands a trailing Price-to-Earnings (P/E) multiple of 53.7x at the minimum price, escalating to a staggering 62.7x at the maximum price boundary. From a balance sheet and asset perspective, incorporating the estimated Rp430.0 billion in net primary proceeds (after underwriting and professional fees), the pro forma post-IPO consolidated equity base is projected to reach approximately Rp1.24 trillion. This yields a Price-to-Book Value (PBV) multiple ranging from a demanding 3.1x to 3.6x.

A comparative analysis against publicly listed hospital operators on the Indonesia Stock Exchange exposes the extraordinarily aggressive nature of this pricing strategy. Direct industry peers such as PT Medikaloka Hermina Tbk ($HEAL), a massive national operator, currently trade at trailing P/E multiples of approximately 42.2x and PBV multiples of 3.25x. Similarly, larger, heavily diversified operators like PT Siloam International Hospitals Tbk ($SILO) and PT Mitra Keluarga Karyasehat Tbk ($MIKA) generally command P/E multiples comfortably in the 30x to 40x range. Smaller, highly profitable niche operators such as PT Kedoya Adyaraya Tbk ($RSGK) trade at significantly more grounded valuations, exhibiting a P/E of 28.9x and a PBV of just 1.2x.

While specialized, tertiary healthcare assets exhibiting high barriers to entry and monopolistic regional dominance occasionally warrant premium multiples, JEC’s recent history fundamentally undermines the justification for a 60x earnings multiple. The severe profitability contraction in 2024, the sluggish recovery in 2025, and the documented breaches of bank covenants paint a picture of an operation struggling under its own weight. The valuation at Rp1,400 per share appears to be priced for absolute, flawless execution and an immediate return to 2023 margin levels, leaving absolutely zero margin of safety for operational missteps, prolonged inflationary pressures on medical supplies, or further regulatory shifts in BPJS reimbursement tariffs.

Integrated Perspectives and Final Investment Stance

Synthesizing the exhaustive analysis of the transaction architecture, regulatory mechanics, macroeconomic environment, and clinical fundamentals requires carefully balancing the undeniable reality of the business against the hostile structural mechanics of the capital market event.

From the perspective of a fundamental, long-term investor, the JEC enterprise represents a highly durable, wide-moat, and culturally significant healthcare asset. The macroeconomic and demographic tailwinds—specifically the aging population and the explosive growth of diabetes-induced optical complications—are indisputable and virtually guarantee a rising demand curve for decades. The brand equity of the JEC network is unparalleled in the domestic ophthalmology space, and the strategic, institutional backing of the Emtek conglomerate through PT Sarana Meditama Metropolitan Tbk provides formidable operational support, technological integration, and procurement synergies. However, this fundamental attractiveness is severely, almost fatally, diluted by the aggressive 60x valuation multiples and the stark reality that the IPO is primarily functioning as a rescue mechanism designed to cure breached debt covenants rather than serving as a springboard for exponential, unencumbered organic expansion.

From an IPO-focused, transactional, and trading standpoint, the mechanical setup is overwhelmingly negative and highly precarious. The presence of a massive 5.00% secondary exit by a key founder immediately siphons vital liquidity away from corporate utility, signaling an insider rush for the exits. More distressingly, the capitalization table is riddled with dozens of individual minority stakeholders who, due to the specific timing of their historical share acquisitions, are entirely exempt from the mandatory OJK lock-up regulations under POJK 25/2017. With only 10.14% of the shares voluntarily restricted by the controlling entity, an unprecedented volume of pre-IPO equity is legally and mechanically free to trade on the very first day of listing. Compounding this severe structural overhang risk is the total, absolute absence of JSON-verifiable underwriter metrics. Without hard data to confirm the absorption capacity, historical hype momentum, or proven pricing discipline of PT Trimegah Sekuritas Indonesia Tbk, investors are flying entirely blind into a potential, unmitigated supply deluge.

The initial public offering of PT Nitrasanata Dharma Tbk presents a stark, irreconcilable divergence between a high-quality clinical enterprise and a highly compromised, deeply flawed transactional structure. While the underlying medical business possesses significant operational merit and occupies a dominant, defensible niche in the Indonesian healthcare landscape, the IPO itself represents a high-risk situation characterized by extreme valuation premiums and severe potential post-offering supply pressure. The capital allocation strategy clearly reveals a defensive maneuver designed to extinguish breached debt covenants and placate anxious lenders, while the concurrent secondary divestment permits early stakeholders to monetize at incredibly demanding multiples. The catastrophic lack of mandatory lock-ups across the highly fragmented founder and physician base creates a structural overhang that could easily overwhelm the secondary market upon listing. Given the complete absence of underwriter performance metrics to provide statistical confidence in market stabilization or demand generation, the risk of a rapid, disorderly post-listing contraction is highly elevated. Consequently, this offering should not be viewed as a fundamentally supported investment opportunity at current pricing levels, but rather as a highly precarious liquidity event fraught with immediate, unquantifiable supply risks.

Final Verdict & Aluna Rating

The initial public offering of PT Nitrasanata Dharma Tbk presents a stark, irreconcilable divergence between a high-quality clinical enterprise, a highly compromised transactional structure, and an immensely powerful underwriter. While the underlying medical business possesses significant operational merit, the IPO structure is plagued by aggressive 60x valuation multiples, a heavy secondary divestment, and a catastrophic lack of mandatory lock-ups across the highly fragmented founder base. This creates a structural overhang that could easily overwhelm the secondary market. However, the presence of LG (PT Trimegah Sekuritas Indonesia Tbk) as the sole underwriter—boasting a 96.51% winrate, a perfect 100.00 Liquidity Score, and “King Maker” status—serves as a massive counterbalance. LG’s historical dominance suggests they will aggressively absorb early insider selling to secure a successful listing, transforming a fundamentally risky, debt-heavy bailout into a highly potent, underwriter-driven short-term trading opportunity.

---

Final Verdict & Aluna Rating

Aluna Analytics Rating: Speculative BUY / High Volatility.
This rating reflects a fierce tug-of-war. The fundamental rating remains Underweight due to the demanding 53x-62x earnings valuation, recent margin compression, defensive debt-repayment focus, and the massive structural overhang from 75% un-locked pre-IPO equity. However, the tactical/trading rating is forcefully upgraded to a Speculative BUY entirely due to the presence of sole underwriter LG. Their “King Maker” status, 96.5% winrate, and 100.00 Liquidity Score indicate a very high probability of successful day-one price defense and engineered momentum, overriding the structural supply risks in the immediate short-term window.